Interim Report January – June 2018
The limited number of mitochondrial therapies means that there is no adequate treatment for a number of diseases and disorders. NeuroVive’s ambition is to translate mitochondrial science into clinical practice.
The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.
NeuroVive’s target is to produce approved pharmaceuticals with the potential for global commercialization. Accordingly, NeuroVive is seeking partnerships with large pharmaceutical companies and/or CCO (contract commercial organization) partners to maximize the potential for commercializing new pharmaceuticals. NeuroVive is also open to outlicensing drug candidates and pharmaceuticals to large pharmaceutical companies for registration, marketing and sale in different phases of the development process.